Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating the drug elacestrant in Japanese post-menopausal women and men with advanced or metastatic breast cancer that is estrogen receptor positive ER and human epidermal growth factor receptor 2 negative HER2-, who also have a specific gene mutation known as ESR1. These participants must have experienced disease progression after 1 to 2 prior endocrine therapy treatments for metastatic breast cancer, including therapy with a CDK46 inhibitor combined with fulvestrant or an aromatase inhibitor. The study is an open-label Phase 2 trial aimed at assessing elacestrants efficacy and safety. Participants will receive elacestrant as a once-daily oral tablet. This is a single-arm study without a placebo group, focusing on treatment with elacestrant. The study will continue for up to approximately 27 months to monitor treatment effects and safety. During the study, participants will undergo evaluations including imaging assessments to measure progression-free survival, adverse event monitoring, and blood tests to measure plasma concentrations of elacestrant. Researchers will also observe overall survival and progression-free survival as assessed by investigators. The total duration for participant involvement aligns with the treatment and follow-up period of up to about 27 months.
Actively Recruiting
Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.
Actively Recruiting
This research aims to provide continued treatment to participants with cancer who are still receiving study therapy in a Genentech or F. Hoffmann-La Roche sponsored trial and who lack local access to these treatments. It involves an open-label, multicenter extension phase where eligible patients can continue on investigational therapies following their original study. Participants will continue receiving Roche investigational medicinal products IMPs either as monotherapy or combined with other agents, following the dosing, schedule, and administration used in their parent study. Treatment can continue until disease progression, loss of clinical benefit, unacceptable toxicity, pregnancy, non-compliance, local treatment availability, withdrawal, or study termination by the sponsor. Throughout the study, participants will be monitored for ongoing access to the study drugs and for adverse events using standardized criteria over approximately 10 years. Safety and clinical benefit assessments will guide continuation. The study offers long-term observation to evaluate treatment continuation and tolerability, with participation lasting until one of the stopping criteria is met or up to the study end date.
Actively Recruiting
Researchers are evaluating new combination treatments for people with locally advanced or metastatic non-small cell lung cancer NSCLC in this Phase II, multi-center, open-label study. The study includes several sub-studies focused on different groups based on tumor genetics and PD-L1 levels, aiming to assess the safety, tolerability, and early anti-tumor effects of these novel regimens. This global study is conducted at approximately 80 centers across 10 countries. Participants receive different combinations of investigational drugs given by intravenous infusion, including rilvegostomig, ramucirumab, and Dato-DXd, depending on their assigned sub-study. Treatments continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. Each sub-study may have a safety run-in phase followed by a dose expansion phase to further evaluate the treatments. Throughout the study, participants undergo regular assessments to monitor tumor response, side effects, and drug levels in the blood. Researchers will track adverse events and measure outcomes like objective response rate, progression-free survival, and overall survival over an average of three years. The study also evaluates pharmacokinetics and immune response to the treatments to better understand how they work and their safety profile.
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults with chronic heart failure who have a reduced left ventricular ejection fraction below 40%. Participants must have been diagnosed with chronic heart failure for at least three months and be in New York Heart Association classes II to IV. The study is a phase III, randomized, double-blind trial aimed at assessing whether this combination improves outcomes compared to placebo plus empagliflozin. Participants are randomly assigned to one of two groups with equal chance one group receives vicadrostat with empagliflozin tablets, and the other receives placebo with empagliflozin tablets. The study medicines are taken once daily for about six months up to three and a half years. Participants continue their regular heart failure treatments alongside the study drugs. The study monitors participants throughout this period, which can last up to 43 months. During the study, participants attend regular visits to the study site and may receive some follow-up calls. They answer questionnaires about their symptoms and overall well-being. Doctors record any worsening heart failure symptoms, hospitalizations due to heart failure, or deaths to compare the two groups. Health status and any side effects are regularly checked. The primary outcome is the time to first cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.
Actively Recruiting
Researchers are evaluating the long-term safety of two drugs, Deucravacitinib and Ustekinumab, in adults with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic treatments. This study is designed to compare these treatments over an extended period, focusing on cardiovascular health and other safety outcomes. The study is sponsored by Bristol-Myers Squibb and is a Phase 3b4 randomized, open-label trial. Participants are randomly assigned to receive either Deucravacitinib or Ustekinumab at specified doses on scheduled days. The study spans up to 5 years, during which participants will be monitored closely for cardiovascular events and other safety outcomes. Treatment adherence and effects will be regularly assessed throughout this long-term safety study. During the study, participants will undergo various evaluations including monitoring for major cardiovascular events such as heart attacks and strokes, other cardiovascular complications, and laboratory assessments including liver function and lipid panels. Researchers will also track serious adverse events and overall mortality up to 60 days after the last dose. This comprehensive monitoring ensures participant safety and gathers essential data on the long-term effects of the treatments over the studys duration, which lasts until January 2031.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of trastuzumab deruxtecan T-DXd combined with rilvegostomig, and T-DXd alone, compared with the standard treatment of gemcitabine, cisplatin, and durvalumab for patients with advanced, untreated HER2-expressing biliary tract cancer. This Phase 3 study focuses on patients with locally advanced or metastatic disease, aiming to compare overall survival and other outcomes across different treatment groups. Participants are assigned to one of three groups one receiving T-DXd and rilvegostomig together, another receiving T-DXd alone, and a third receiving the standard care of gemcitabine, cisplatin, and durvalumab. All treatments are given by intravenous infusion. The study includes an initial safety run-in phase followed by a randomized portion where patients receive assigned treatments until disease progression or other criteria are met. The study is estimated to continue for up to 50 months after the first patient is randomized. During the trial, participants will have tumor samples collected, and their disease will be monitored through imaging and clinical assessments. Researchers will evaluate safety, tolerability, overall survival, progression-free survival, response rates, and patient-reported outcomes like side effects and physical functioning. Blood samples will be taken to study drug levels and immune responses. The study plans to follow participants for long-term outcomes and side effects, with regular visits scheduled throughout the study duration.
1-10 of 13
1